

Explanatory Note

- Merck nv/sa | Brusselsesteenweg 288 | 3090 Overijse | Belgium –
an affiliate of Merck KGaA, Darmstadt, Germany

1. Introduction

Company conducts the disclosure according to the Sunshine Act (chapter 1 of title 3 of the Law of 18 December 2016 regarding various provisions on health, *Belgian official Journal* 27 December 2016), and RD Sunshine Act (Royal Decree of 14 June 2017 executing the Sunshine Act, *Belgian official Journal* 23 June 2017).

As per the related Frequently Asked Questions, Sunshine Act, document, paragraph 9, this Explanatory Note addresses two topics - “company subject to notification” information, and additional information on the premiums and benefits relating to Patient Associations.

2. Company subject to notification

As per the Frequently Asked Questions, Sunshine Act Document, paragraph 2, point c, both, companies established in Belgium as abroad are included in the concept of “company subject to notification”.

Company discloses any payments, done by any company’s Belgian local entities, as well as payments done by any other company’s legal entities abroad, in a single publication.

3. **Additional Information on the premiums and benefits relating to Patient Associations** can be found on

<https://www.merckgroup.com/en/sustainability/products-and-businesses/transparency/efpia-patient-organisation-reporting.html>